| 发明名称 |
HISTONE DEACETYLASE 6 (HDAC6) BIOMARKERS IN MULTIPLE MYELOMA |
| 摘要 |
The invention relates to histone deacetylase (HDAC) biomarkers in multiple myeloma. Specifically, the biomarkers are drug specific, histone deacetylase (HDAC) or HDAC6 biomarker RNAs for multiple myeloma. The invention also relates to a kit for determining the treatment efficiency of a HDAC6 inhibitor, and a kit for identifying a histone deacetylase 6 (HDAC6) inhibitor. The invention further relates to a method for monitoring treatment efficiency of an HDAC inhibitor in a subject. |
| 申请公布号 |
US2015176076(A1) |
申请公布日期 |
2015.06.25 |
| 申请号 |
US201414576313 |
申请日期 |
2014.12.19 |
| 申请人 |
Acetylon Pharmaceuticals, Inc. |
发明人 |
Yang Min;Tamang David Lee;Jones Simon Stewart |
| 分类号 |
C12Q1/68;A61K31/505 |
主分类号 |
C12Q1/68 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A kit for determining the treatment efficiency of a histone deacetylase 6 (HDAC6) inhibitor in a subject having multiple myeloma comprising:
a detection agent that specifically binds to a HDAC6 biomarker RNA (ribonucleic acid) selected from the group consisting of SEQ ID NOs: 1-27; and instructions for measuring the expression level of a HDAC6 biomarker RNA comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-27. |
| 地址 |
Boston MA US |
